FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology ...
Institute of Protein Research of the Russian Academy of Sciences, Pushchino, Moscow Region 142290, Russian Federation Pushchino Branch, Shemyakin−Ovchinnikov Institute of Bioorganic Chemistry of the ...
Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date FRAMINGHAM, MA / ACCESS Newswire / July 23, ...
The protein DNase1 is one of the oldest biological agents in history: It has been on the market since 1958 and is now used, among other things, to treat cystic fibrosis. However, it takes considerable ...
Findings demonstrate that by degrading neutrophil extracellular traps (NETs), DNase I not only facilitates increased T cell infiltration but also restores T cell functionality, paving the way for more ...
Acute ischemic stroke treatment typically involves tissue-type plasminogen activator (tPA) or tenecteplase, but about 50% of patients do not achieve successful reperfusion. The causes of tPA ...
An interview with Dr. Dirk M. Hermann, Professor of Neurology at University Hospital Essen, University of Duisburg-Essen, Germany. Interviewed by Dr. Hansen Chen, PhD, Instructor, Department of ...
Editorial Note: Talk Android may contain affiliate links on some articles. If you make a purchase through these links, we will earn a commission at no extra cost to you. Learn more. Photo by Mitchell ...
Xenetic (XBIO) Biosciences announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I with chimeric antigen receptor T cells in a syngeneic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results